- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lucio Gordan Discusses Updated Guidelines Addressing 1q Abnormalities in Multiple Myeloma
Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
In this edition of Managed Care Cast, Executive Editor Mary Caffrey speaks with Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute. Gordan discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
Review the NCCN guideline update discussed in this podcast.
The guidelines follow the Second revision of the International Staging System (R2-ISS), which appeared in the December 2022 issue of the Journal of Clinical Oncology, the official publication of the American Society of Clinical Oncology.1
Listen above or on one of these podcast services:
Reference
- D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the Harmony project. J Clin Oncol 2022;40(29):3406-3418. doi:10.1200/JCO.21.02614
How Do Community Oncologists View the Use of MRD Testing?
October 1st 2024Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.
Read More
